Sanofi "Satisfied" In Third Quarter
French health and beauty company Sanofi said that "satisfying trends were maintained" in the 1996 third quarter. The firm achieved total sales of just under 17 billion French francs ($3.3 billion) in the first nine months of 1996, up 1.5% or 2.9% at constant exchange rates.
Human health care turnover amounted to 13.8 billion francs, up 2.3% (3.9% CER). The firm said that the growth rate for pharmaceutical sales observed in the first half of 1996 was maintained thanks to major internationally established products. Sales growth was sustained in western Europe, up 7%, in central and eastern Europe turnover advanced 26%, in Asia it grew 17%, and in Latin America pharmaceutical revenues were up 8%. The firm noted that a decline in sales in the USA stabilized in the third quarter.
During the quarter, Sanofi filed for a product license approval for its antihypertensive agent irbesartan in the USA and in Europe.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze